Skip to main content
Premium Trial:

Request an Annual Quote

BG Medicine Partners with Siemens on Automated Version of Galectin-3 Heart Failure Prognostic


BG Medicine this week announced it is partnering with Siemens Healthcare Diagnostics on the development and commercialization of an automated version of its galectin-3 protein biomarker prognostic for chronic heart failure patients.

The manual version of the test received approval from the US Food and Drug Administration in November, and BGM is currently finalizing commercialization plans with the Laboratory Corporation of America.

In its recently amended preliminary prospectus for its initial public offering, the company said it believes an automated version of the test will be required for it "to achieve broad customer acceptance and clinical adoption." The filing also said BGM hopes to submit a 510(k) pre-market notification to the FDA for an automated test by the fourth quarter of 2011, and to have such a test on the market in the first half of 2012 (PM 12/3/2010).

According to a statement released by BGM this week, under the agreement Siemens will be responsible for "the development of the test in accordance with certain plans and milestones," and both firms "will collaborate in support of development of the test and regulatory filings."

In addition to the Siemens agreement, the company has signed deals with Abbott, Alere, and BioMérieux for the development and commercialization of automated galectin-3 tests.

Also this week, BGM announced the publication of a study in the Annals of Medicine by the Department of Cardiology at the University Medical Centre Groningen in the Netherlands that suggests galectin-3 could be useful as a biomarker for predicting adverse outcomes in heart failure patients with preserved ejection fraction and reduced ejection fraction.

According to the study, this was the first time galectin-3 data had been published on patients with preserved ejection fraction, which make up roughly half of all heart failure patients.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more